Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quaratusugene ozeplasmid - Genprex/University of Texas M D Anderson Cancer Center

Drug Profile

Quaratusugene ozeplasmid - Genprex/University of Texas M D Anderson Cancer Center

Alternative Names: CNVN 202; DOTAP Chol-TUSC2 Liposomal Complex; DOTAP-Chol-fus1; DOTAP-Cholesterol-Fus1 liposome complex; FUS1 cancer gene therapy; GPX 001; INGN-401; ONC-001; ONC-002; ONC-003; ONC-004; Oncoprex; REQORSA; TUSC2 immunogene therapy; TUSC2-nanoparticles

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Genprex; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; TUSC2 protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Small cell lung cancer
  • Discontinued Triple negative breast cancer

Most Recent Events

  • 12 Mar 2024 Genprex has patent protection for Quaratusugene ozeplasmid in South Korea
  • 06 Mar 2024 Pharmacodynamics data from preclinical trial in Non small cell lung cancer released by Genprex
  • 02 Feb 2024 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05703971)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top